(Q58453418)

Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study

21 January 2018

1 reference

Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology.

21 January 2018

1 reference

Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States.

21 January 2018

1 reference

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

21 January 2018

1 reference

Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas

21 January 2018

1 reference

Activation of a novel human transforming gene, ret, by DNA rearrangement

21 January 2018

1 reference

Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation

21 January 2018

1 reference

RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma

21 January 2018

1 reference

Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.

21 January 2018

1 reference

The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2.

21 January 2018

1 reference

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis

21 January 2018

1 reference

Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

21 January 2018

1 reference

ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?

21 January 2018

1 reference

Ret and trk proto-oncogene activation in thyroid papillary carcinomas in French patients from the Champagne-Ardenne region

21 January 2018

1 reference

RET/PTC rearrangement in thyroid tumors

21 January 2018

1 reference

RET oncogene activation in papillary thyroid carcinoma.

21 January 2018

1 reference

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

Pathogenetic mechanisms in thyroid follicular-cell neoplasia

21 January 2018

1 reference

On Trk for retrograde signaling

21 January 2018

1 reference

Chromosomal rearrangements in thyroid carcinomas: a recombination or death dilemma

21 January 2018

1 reference

NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident

21 January 2018

1 reference

21 January 2018

1 reference

Predisposition to neoplastic transformation caused by gene replacement of H-ras1.

21 January 2018

1 reference

RAS: target for cancer therapy

21 January 2018

1 reference

Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

21 January 2018

1 reference

H-ras protooncogene mutations in human thyroid neoplasms

21 January 2018

1 reference

Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas

21 January 2018

1 reference

Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo

21 January 2018

1 reference

N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.

21 January 2018

1 reference

Prevalence of activating ras mutations in morphologically characterized thyroid nodules.

21 January 2018

1 reference

ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

21 January 2018

1 reference

Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma

21 January 2018

1 reference

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).

21 January 2018

1 reference

Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.

21 January 2018

1 reference

A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma.

21 January 2018

1 reference

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer

21 January 2018

1 reference

Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas

21 January 2018

1 reference

BRAF mutation in thyroid cancer

21 January 2018

1 reference

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

21 January 2018

1 reference

BRAF mutations in papillary carcinomas of the thyroid

21 January 2018

1 reference

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

21 January 2018

1 reference

Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population

21 January 2018

1 reference

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

21 January 2018

1 reference

Mutation of the PIK3CA gene in anaplastic thyroid cancer.

21 January 2018

1 reference

PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1

21 January 2018

1 reference

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]

21 January 2018

1 reference

The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition

21 January 2018

1 reference

PAX8PPARgamma stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line

21 January 2018

1 reference

PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth

21 January 2018

1 reference

Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas.

21 January 2018

1 reference

Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors.

21 January 2018

1 reference

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

21 January 2018

1 reference

Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification

21 January 2018

1 reference

Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo

21 January 2018

1 reference

Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function

21 January 2018

1 reference

Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity

21 January 2018

1 reference

Galectins in regulation of apoptosis

21 January 2018

1 reference

Galectins as modulators of tumour progression

21 January 2018

1 reference

Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions

21 January 2018

1 reference

Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma.

21 January 2018

1 reference

Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation

21 January 2018

1 reference

Continuing controversies in the management of thyroid nodules

21 January 2018

1 reference

Regulation of GSK-3 beta in the proliferation and apoptosis of human thyrocytes investigated using a GSK-3 beta-targeting RNAi adenovirus expression vector: involvement the Wnt/beta-catenin pathway

21 January 2018

1 reference

Wnt/β-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells

21 January 2018

1 reference

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

21 January 2018

1 reference

The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.

21 January 2018

1 reference

Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis

21 January 2018

1 reference

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling

21 January 2018

1 reference

Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion

21 January 2018

1 reference

Combinatorial microRNA target predictions

21 January 2018

1 reference

Gene methylation in thyroid tumorigenesis

21 January 2018

1 reference

DNA methylation patterns and epigenetic memory

21 January 2018

1 reference

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

PTEN promoter methylation in sporadic thyroid carcinomas.

21 January 2018

1 reference

Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis.

21 January 2018

1 reference

Quantitative assessment of promoter methylation profiles in thyroid neoplasms.

21 January 2018

1 reference

Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer

21 January 2018

1 reference

Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors

21 January 2018

1 reference

Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference

21 January 2018

1 reference

Molecular diagnostics and predictors in thyroid cancer

21 January 2018

1 reference

Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status

21 January 2018

1 reference

BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population.

21 January 2018

1 reference

BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.

21 January 2018

1 reference

Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.

21 January 2018

1 reference

Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement

21 January 2018

1 reference

Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas.

21 January 2018

1 reference

Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules

21 January 2018

1 reference

BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.

21 January 2018

1 reference

Diagnostic use of molecular markers in the evaluation of thyroid nodules

21 January 2018

1 reference

The prevalence and prognostic value of BRAF mutation in thyroid cancer

21 January 2018

1 reference

Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies

21 January 2018

1 reference

Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy

21 January 2018

1 reference

Preoperative diagnosis of benign thyroid nodules with indeterminate cytology

21 January 2018

1 reference

Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens

21 January 2018

1 reference

The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology

21 January 2018

1 reference

The interobserver reproducibility of thyroid fine-needle aspiration using the UK Royal College of Pathologists' classification system.

21 January 2018

1 reference

MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility

21 January 2018

1 reference

MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases

21 January 2018

1 reference

MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma

21 January 2018

1 reference

Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma

21 January 2018

1 reference

miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.

21 January 2018

1 reference

Predictive and prognostic molecular markers for cancer medicine

21 January 2018

1 reference

Prognostic utility of BRAF mutation in papillary thyroid cancer

21 January 2018

1 reference

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

21 January 2018

1 reference

BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer

21 January 2018

1 reference

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

21 January 2018

1 reference

The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer

21 January 2018

1 reference

Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.

21 January 2018

1 reference

BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer

21 January 2018

1 reference

Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

21 January 2018

1 reference

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer

21 January 2018

1 reference

Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis

21 January 2018

1 reference

Highly prevalent TERT promoter mutations in aggressive thyroid cancers

21 January 2018

1 reference

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence

21 January 2018

1 reference